SRX3305 是一种 BTK/PI3K/BRD4 抑制剂,对 BTK、PI3Kα 和 PI3Kδ 的 IC50 值分别为 6.5 nM、15 nM 和 4 nM,能以剂量依赖的方式抑制慢性淋巴细胞白血病 (CLL) 和套细胞淋巴瘤 (MCL) 细胞的增殖并促进细胞凋亡 (apoptosis),具有强效的抗肿瘤作用而不损害健康细胞,在体外可抑制原代 CLL 细胞的活化诱导增殖并有效阻断微环境介导的生存信号,还可抑制 CLL 细胞向 CXCL-12 和 CXCL-13 的迁移,且在对 Ibrutinib (MS-M40234) 耐药的 CLL 细胞中仍保持其抗肿瘤活性,可用于 CLL、弥漫性大 B 细胞淋巴瘤 (DLBCL) 和 MCL 的研究。
产品编号: MS-S44439 CAS No.: 2409965-28-0 分子式: C22H20N2O5S 分子量: 424.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

SRX3305 是一种 BTK/PI3K/BRD4 抑制剂,对 BTK、PI3Kα 和 PI3Kδ 的 IC50 值分别为 6.5 nM、15 nM 和 4 nM,能以剂量依赖的方式抑制慢性淋巴细胞白血病 (CLL) 和套细胞淋巴瘤 (MCL) 细胞的增殖并促进细胞凋亡 (apoptosis),具有强效的抗肿瘤作用而不损害健康细胞,在体外可抑制原代 CLL 细胞的活化诱导增殖并有效阻断微环境介导的生存信号,还可抑制 CLL 细胞向 CXCL-12 和 CXCL-13 的迁移,且在对 Ibrutinib (MS-M40234) 耐药的 CLL 细胞中仍保持其抗肿瘤活性,可用于 CLL、弥漫性大 B 细胞淋巴瘤 (DLBCL) 和 MCL 的研究。

生物实验数据

生物活性 SRX3305 is a BTK/PI3K/BRD4 inhibitor with IC50 values of 6.5 nM, 15 nM, and 4 nM for BTK, PI3Kα, and PI3Kδ, respectively; it inhibits the proliferation of and promotes apoptosis in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) cells in a dose-dependent manner, exerts potent antitumor effects without harming healthy cells, inhibits activation-induced proliferation of primary CLL cells in vitro and effectively blocks microenvironment-mediated survival signals, also inhibits the migration of CLL cells toward CXCL-12 and CXCL-13, retains its antitumor activity in Ibrutinib (MS-M40234)-resistant CLL cells, and can be used for research on CLL, diffuse large B-cell lymphoma (DLBCL), and MCL.
IC50 & Target PI3Kα:15 nM
体外研究
(In Vitro)

SRX3305 (0.1-100 μM;72 小时) 可抑制 B-NHL 细胞系的增殖,平均 IC50 值为 1.38 µM。
SRX3305 (0.1-100 μM;72 小时) 可降低 DLBCL 细胞的增殖,在 OCI-LY3 细胞中的 IC50 值约为 290 nM,在 SU-DHL-6 细胞中的 IC50 值约为 920 nM。
SRX3305 (0.5-2 μM;24-48 小时) 可剂量依赖性地诱导 HG-3 和 OSU-CLL 细胞凋亡。
SRX3305 (0.5-2 μM;4 小时) 可抑制 OSU-CLL、MEC-1 和 MEC-2 细胞系中的关键 BCR 存活信号通路。
SRX3305 (0.16-5 μM;48 小时) 可抑制从 Eμ-TCL1 (CLL 模型) 和 Eμ-Myc/TCL1 小鼠中分离的恶性 B 细胞的存活和增殖。
SRX3305 (0.5-2 μM;48 小时) 可破坏 CLL 中基质对细胞存活的支持作用以及趋化因子诱导的细胞迁移。
SRX3305 (0.5-2 μM;48 小时) 可克服 MEC-1 细胞中 TME 诱导的存活信号通路。。
SRX3305 (0.1-100 μM;72 小时) 对伊布替尼耐药的 HG-3 细胞具有活性。
SRX3305 (10 nM-100 μM;48 小时) 在 Mino 细胞中的 IC50 为 1 nM,在 JeKo-1 细胞中为 58 nM,在 Granta 细胞中为 1.1 μM,在 JeKo-1 BTK C481S 突变细胞中为 1 μM,在 Mino BTK C481S 突变细胞中为 47 nM。
SRX3305 (0.375-2 μM;48 小时) 对健康供体外周血单核细胞 (PBMC) 或周围健康基质细胞的毒性极低,对健康供体 B 细胞的毒性也很低。
SRX3305 (0.1-10 μM;48 小时) 对原发性 Eμ-Myc 肿瘤样本具有抗肿瘤作用。
SRX3305 (0.01-0.5 μM;1 小时) 可阻断 BTK 和 AKT 的激活。
SRX3305 (0.01-1 μM;1 小时) 在 MCL 细胞和伊布替尼耐药的 MCL 细胞中显示出更高的疗效。
在抑制剂洗脱实验后,SRX3305 (1 小时) 仍能抑制 Mino 细胞中的 BTK 和 AKT 磷酸化。
SRX3305 (0.5-2 μM; 24 小时) 通过诱导 S/G2 期细胞周期停滞和促进细胞凋亡来抑制 JeKo-1 和 Mino 细胞增殖。

Cell Proliferation Assay

Cell Line: B-cell non-Hodgkin lymphoma cell lines
Concentration: 0.1 μM; 1 μM; 10 μM; 100 μM
Incubation Time: 72 h
Result: Significantly inhibited CLL cell proliferation in a dose-dependent manner.

Apoptosis Analysis

Cell Line: HG-3 and OSU-CLL cell lines
Concentration: 0.5 μM; 1 μM; 2 μM
Incubation Time: 24 h; 48 h
Result: Induced apoptosis in a dose-dependent manner.

Western Blot Analysis

Cell Line: OSU-CLL, MEC-1 and MEC-2 cell lines
Concentration: 0.5 μM; 1 μM; 2 μM
Incubation Time: 4 h
Result: Effectively inhibited the phosphorylation of BTK and PRAS40 (indicative of PI3K/AKT signaling) and reduced MYC expression.

Western Blot Analysis

Cell Line: OSU-CLL and MEC-1 cell lines
Concentration: 0.5 μM plus inhibitor treatment; 1 μM plus inhibitor treatment; 2 μM plus inhibitor treatment
Incubation Time: 4 h
Result: Decreased phosphorylation of BTK (p-BTK) and PRAS40 (p-PRAS40) and reduced MYC expression in continuous inhibitor treatment.
Retained the inhibition of p-BTK following treatment washout.
Marked inhibition of p-PRAS40 and MYC expression after treatment washout was maintained.

Cell Proliferation Assay

Cell Line: patient-derived CLL cells
Concentration: 0.16 μM plus CpG (3.2 μM); 0.31 μM plus CpG (3.2 μM); 0.63 μM plus CpG (3.2 μM); 1.25 μM plus CpG (3.2 μM); 2.5 μM plus CpG (3.2 μM); 5 μM plus CpG (3.2 μM)
Incubation Time: 48 h
Result: Reversed CpG ODN-mediated proliferation reflected by reduced MYC levels in primary CLL cells.

Western Blot Analysis

Cell Line: patient-derived CLL cells
Concentration: 0.5 μM plus CpG (3.2 μM); 1 μM plus CpG (3.2 μM); 2 μM plus CpG (3.2 μM)
Incubation Time: 48 h
Result: Induced the accumulation of P21 (cyclin-dependent kinase inhibitor), indicative of cell cycle arrest.
Did not influence the proliferation under unstimulated/basal conditions.

Cell Cytotoxicity Assay

Cell Line: malignant B-cells isolated from Eμ-TCL1 (CLL model) and Eμ-Myc/TCL1 mice
Concentration: 0.5 μM; 1 μM; 2 μM
Incubation Time: 48 h
Result: Induced significant cytotoxicity in Eμ-TCL1 and Eμ-Myc/TCL1-derived malignant cells in a dose-dependent manner, suggesting promising therapeutic benefits in aggressive CLL and associated lymphomas.

Cell Viability Assay

Cell Line: co-culture of primary CLL cells on BM-derived stromal cells
Concentration: 0.5 μM; 1 μM; 2 μM
Incubation Time: 48 h
Result: Reduced CLL cell viability in a dose-dependent manner despite stroma protection.
Did not have toxicity to the stromal cells, indicating that CLL cell cytotoxicity is not a function of reduced stroma viability.

Cell Migration Assay

Cell Line: MEC-1 cells
Concentration: 0.5 μM; 1 μM; 2 μM
Incubation Time: 48 h
Result: Reduced the migration of MEC-1 cells towards CXCL-12 or CXCL-13.

Cell Proliferation Assay

Cell Line: ibrutinib-resistant HG-3 cells
Concentration: 0.1 μM; 1 μM; 10 μM; 100 μM
Incubation Time: 72 h
Result: Remarkably decreased cell proliferation.

Western Blot Analysis

Cell Line: ibrutinib-resistant HG-3 cells
Concentration: 1 μM; 2 μM
Incubation Time: 4 h
Result: Consistently decreased MYC expression and p-PRAS40 (PI3K target) and increased P21 levels in IR-HG3 cells.
Reduced BTK activation (phosphorylation).

Cell Viability Assay

Cell Line: MCL cell lines JeKo-1, Mino, JeKo-1 BTK C481S and Mino BTK C481S
Concentration: 10 nM; 100 nM; 1 μM; 10 μM; 100 μM
Incubation Time: 48 h
Result: Exhibited strong anti-proliferative function.

Cell Viability Assay

Cell Line: PBMCs
Concentration: 0.375 μM; 0.75 μM; 1.5 μM
Incubation Time: 48 h
Result: Had minimally toxicity.

Cell Viability Assay

Cell Line: healthy donor B-cells
Concentration: 0.5 μM
Incubation Time: 48 h
Result: Exhibited low toxicity.

Cell Viability Assay

Cell Line: bystander healthy stromal cells
Concentration: 0.5 μM; 1 μM; 2 μM
Incubation Time: 48 h
Result: Had minimally toxicity.

Cell Viability Assay

Cell Line: primary Eμ-Myc tumor cells
Concentration:

化学信息

分子量 424.47
分子式 C22H20N2O5S
CAS No. 2409965-28-0

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础

  • 客服

    2851296953

    18923798467

    微信洽谈